Karyopharm Therapeutics Inc Shares Up 20.8% After Hours Following Positive Trial Data From STORM Study For Selinexor; Co. To Submit NDA For Selinexor For Penta-Refractory Multiple Myeloma During 2H'18
Brad Hammond